<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30179779</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>04</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1532-3080</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>42</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>28</Day>                    </PubDate>                </JournalIssue>                <Title>Breast (Edinburgh, Scotland)</Title>                <ISOAbbreviation>Breast</ISOAbbreviation>            </Journal>            <ArticleTitle>Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy.</ArticleTitle>            <Pagination>                <MedlinePgn>61-67</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0960-9776(18)30257-1</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.breast.2018.08.103</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pregnancy-associated breast cancer (PABC) refers to breast cancers (BC) diagnosed during pregnancy or shortly after birth. Although the inflammatory environment of post-partum PABC cases (designed as PP-PABC) may be deleterious, so far PP-PABC have scarcely been distinguished from breast cancers diagnosed during pregnancy. Furthermore, whether PP-PABC cases have an enhanced immune infiltration remains unknown. We investigated chemosensitivity, immune infiltration and survival of PP-PABC patients treated by neoadjuvant chemotherapy (NAC) compared to non-PABC matched BC patients.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We identified PP-PABC cases among a cohort of 1199 invasive BC treated with NAC between 2002 and 2012. Each PP-PABC case was matched with 3 non-PABC controls, according to age and pathological breast cancer subtype. Microbiopsy specimens and paired surgical samples were evaluated for stromal lymphocyte infiltration. Association of clinical and pathological factors with pathological complete response (pCR) and disease-free survival (DFS) was assessed by univariate and multivariate analyses.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Our final population study was composed of 116 patients (29 PP-PABC and 87 non-PABC). Median follow-up was of 49.0 and 29.3 months, respectively. After NAC, pCR rates (p = 0.64), post-NAC immune infiltration (stromal TILs: p = 0.67; intratumoral TILs: p = 0.14), and DFS rates (p = 0.17) were comparable between PP-PABC and non-PABC patients in global population. Similar results were found after stratification by pathological subtype.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We observed similar patterns between postpartum PABC and control tumors in terms of chemosensitivity, immune infiltration, and prognostic. Our results enhance the idea that PP-PABC should receive the same standard of care treatment as other patients, including neoadjuvant chemotherapy.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Labrosse</LastName>                    <ForeName>Julie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Electronic address: julie.labrosse3@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abdennebi</LastName>                    <ForeName>Inès</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Electronic address: ines.abdennebi@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Thibault</LastName>                    <ForeName>Lucie</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Centre René Huguenin- Institut Curie, 35 Rue Dailly, 92210 St Cloud, France. Electronic address: lucie.thibault@curie.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Laas</LastName>                    <ForeName>Enora</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Electronic address: enora.laas@curie.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Merckelbagh</LastName>                    <ForeName>Hilde</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Port-Royal Maternity Unit, 123 Boulevard de Port Royal, 75014 Paris, France. Electronic address: hildemerckelbagh@yahoo.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morel</LastName>                    <ForeName>Charlotte</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Electronic address: charlotte-morel@live.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lam</LastName>                    <ForeName>Thanh</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology and Obstetrics, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland. Electronic address: lamgiangthanh@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lae</LastName>                    <ForeName>Marick</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Centre René Huguenin- Institut Curie, 35 Rue Dailly, 92210 St Cloud, France. Electronic address: marick.lae@curie.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Reyal</LastName>                    <ForeName>Fabien</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005 Paris, France; Residual Tumor &amp; Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d'Ulm, Paris, France. Electronic address: fabien.reyal@curie.fr.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hamy</LastName>                    <ForeName>Anne-Sophie</ForeName>                    <Initials>AS</Initials>                    <AffiliationInfo>                        <Affiliation>Residual Tumor &amp; Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, INSERM, U932 Immunity and Cancer, Institut Curie, 26 rue d'Ulm, Paris, France. Electronic address: anne-sophie.hamy-petit@curie.fr.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Breast</MedlineTA>            <NlmUniqueID>9213011</NlmUniqueID>            <ISSNLinking>0960-9776</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Chemosensitivity</Keyword>            <Keyword MajorTopicYN="N">PABC</Keyword>            <Keyword MajorTopicYN="N">Post-partum breast cancer</Keyword>            <Keyword MajorTopicYN="N">Pregnancy associated breast cancer</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>            <Keyword MajorTopicYN="N">TILs</Keyword>            <Keyword MajorTopicYN="N">Tumor infiltrating lymphocytes</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>5</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30179779</ArticleId>            <ArticleId IdType="pii">S0960-9776(18)30257-1</ArticleId>            <ArticleId IdType="doi">10.1016/j.breast.2018.08.103</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>